Introduction
============

Systemic anticancer therapy (SACT)
----------------------------------

There are many different treatment options for lung cancer, and these are influenced by type, extent and progression of disease. These treatments can be categorised into surgery, radiotherapy and systemic anticancer therapy (SACT), combinations of which are also possible. While surgery and radiotherapy tend to be of use in local, early-stage disease, SACT is largely used as first-line treatment in advanced stage IIIb-IV non-small-cell lung cancer (NSCLC), with extensive nodal involvement and metastases, to 'improve survival, disease control and quality of life' and is the preferred treatment for both limited and extensive small-cell lung cancer (SCLC) \[[@ref1]\]. It is planned in cycles, between which the patient is reviewed for response to therapy.

SACT can be divided into three categories, based on mechanism of action in treating cancer. The most extensive group, chemotherapy, involves the use of cytotoxic drugs to directly destroy tumour cells. It has multiple applications in NSCLC, due to the various intentions of use across most stages of lung cancer. As an adjunct or in combination with radiotherapy, it can be considered pre-operatively in early-disease (stage I--II) patients suitable for surgery; adjuvant chemotherapy aiming to kill cancer cells following radiotherapy is an option in stage II--III disease \[[@ref2]\]. There are multiple classes of chemotherapy drug available, with a variety of intracellular targets such as DNA and microtubules. Biological therapies, the second group, are anticancer agents that prevent the spread of cancer by 'interfering with specific molecules involved in tumour growth and progression' \[[@ref3]\], as opposed to killing tumour cells directly. These targeted therapies have further developed as a result of advancements in tumour analysis for protein mutations that cause uncontrolled proliferation, such as those in epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) \[[@ref4]\]. The third mechanism of SACT is immunotherapy, where monoclonal antibodies recruit the immune system to recognise and attack malignant cells \[[@ref5]\]. [Table 1](#table1){ref-type="table"} details the SACT agents recommended for use in lung cancer.

Application of SACT involves the use of combination therapies. The most recent statistics of the commonest regimens for lung cancer are shown in [Figure 1](#figure1){ref-type="fig"}.

Supportive care medicines are often prescribed as part of the SACT regimen to prevent side effects from occurring. These include various antiemetics such as aprepitant, domperidone, and ondansetron, to combat nausea and vomiting, a common adverse effect of most anticancer agents \[[@ref6]\]. Notably, some have higher potential for nausea than others, particularly cisplatin, and different regimens thus require varying doses of antiemetic \[[@ref17]\]. Corticosteroids, such as dexamethasone, also counter nausea but additionally reduce the incidence and severity of skin rash, another frequent adverse reaction \[[@ref6]\]. Other medicines include folic acid and vitamin B12 for the antifolate drug pemetrexed \[[@ref18], [@ref19]\] and hydration guidelines for the nephrotoxic platinum-based compounds \[[@ref20]\], encompassing combinations of oral furosemide, intravenous saline, and magnesium or potassium salt solutions \[[@ref21], [@ref22]\].

Drug--drug interactions
=======================

As discussed, cancer patients for whom SACT is indicated take a multitude of medicines, either within a complex regimen or due to a range of supportive therapies \[[@ref23]\]. This increases the likelihood of drug--drug interactions (DDIs), where concurrent administration of two drugs allows one to influence the activity of another \[[@ref24]\]. Moreover, interlinking these factors, older patients are the typical demographic of cancer and thus are more likely to be taking multiple regular medicines due to increased comorbidities \[[@ref25]--[@ref27]\].

DDIs, including those involving SACT medicines, can be beneficial and lead to a synergistic (augmented) effect of both drugs, a concept utilised in combination anticancer therapy \[[@ref28]\]. However, there is potential for negative outcomes; due to the large number and difference in mechanisms of action between anticancer agents, there are a multitude of adverse DDIs involving chemotherapy drugs \[[@ref28], [@ref29]\]. Importantly, several SACT agents, including cisplatin, crizotinib, and EGFR tyrosine kinase inhibitors (TKIs), are CYP450 substrates, meaning they can influence hepatic metabolism of many drugs \[[@ref29], [@ref30]\]. Other possible DDIs include platinum-based compounds with nephrotoxic agents such as NSAIDs, a synergistic interaction causing impaired renal function \[[@ref31]\], and EGFR-TKIs with antacids, which raise stomach pH and thus prevent absorption of the anticancer agent \[[@ref32]\].

The impact of DDIs directly on healthcare is poorly characterised. However, the broader group of adverse drug reactions (ADRs) place a significant strain on patients and hospitals, accounting for 6.5% of all hospital admissions, with a total cost per year of over £500,000 to the NHS \[[@ref33], [@ref34]\]. The proportion of this attributed to DDIs is debatable; some suggest an increased risk of readmission related to DDIs \[[@ref35]\], particularly in the elderly \[[@ref36]\], while other reviews propose the opposite \[[@ref37], [@ref38]\]. Nevertheless, as the potential for DDIs in SACT patients is high, methods to increase awareness are crucial to minimise risk of adverse events with which they are associated \[[@ref39], [@ref40]\].

Medicines reconciliation
------------------------

With regard to safe medicine prescribing, it is important that healthcare professionals (HCPs) are conscientious in maintaining the efficacy of medicines, in order for patients to get the best out of their treatment \[[@ref27], [@ref41]\]. This concept is known as medicines optimisation and comprises four guiding principles to improve patient outcome, as outlined by the Royal Pharmaceutical Society \[[@ref42]\]: aiming to understand the patient's experience; evidence-based choice of medicines; ensuring medicines use is as safe as possible; and making medicines optimisation part of routine practice. A major aspect of medicines optimisation that contributes to these aims is medicines reconciliation (Med-Rec), the process of ensuring the medicines a patient is taking are correctly documented \[[@ref43]\].

This involves 'creating and maintaining the most accurate list possible' of the patient's medicines, and then 'comparing... with the current list in use, recognising any discrepancies, and documenting any changes, thereby resulting in a complete list of medicines, accurately communicated' \[[@ref27], [@ref44]\], as defined by the Institute of Healthcare Improvement (IHI). These tasks can be summarised into three elements to form 'reliable' reconciliation: verification of the list of current medicines; validation (a review of the current medicines by a trained and competent HCP, noting whether to continue or alter any doses); and clarification, where the current list is compared with the prescribed 'medication order' \[[@ref41], [@ref44]\].

Previous studies highlight the potential for problems in healthcare without a formal Med-Rec procedure; unintentional discrepancies were found in 70% of medicines prescribed on admission (covering 60% of patients) in a large systematic review by Garfield \[[@ref41], [@ref45]\]. Actively implementing the process is also found to be beneficial; it decreases the rate of 'medication errors' by 70% and ADRs by 15% \[[@ref44], [@ref46], [@ref47]\] in one hospital setting, while another trial found that it reduced potential ADRs by 80% \[[@ref48]\]. This suggests Med-Rec is an important part of preventing harm to patients.

Rationale for study
-------------------

As clarified, there is a considerable risk of DDIs occurring between anticancer agents, plus various supportive care medicines as part of SACT regimens, and other medicines being taken by patients. The complexity of regimens in lung cancer specifically, utilising drugs with various mechanisms, adds to the potential risk of harm. It was therefore of interest to characterise the severity of these potential DDIs (PDDIs), and review whether established processes of Med-Rec, or simply documentation of PDDIs, could have a role in preventing harm. Numerous studies report aspects of these separately: DDIs involving general chemotherapy have been identified retrospectively in several studies \[[@ref49]--[@ref55]\]; while outcomes of pharmacy-led intervention with Med-Rec \[[@ref39], [@ref56]--[@ref62]\] have also been analysed. However, combining severity of PDDIs and improvement of patient safety has not been carried out previously.

Aims, objectives and standards
==============================

Aims
----

The aim is to evaluate the potential for DDIs between medicines in SACT regimens and other medicines taken by lung cancer patients treated at Chelsea and Westminster Hospital (CWH).

Objectives
----------

1.  To identify and characterise PDDIs present between SACT medicines (comprising anticancer agents and supportive care medicines) and other medicines taken by the patients.

2.  To assess the process of Med-Rec and evaluate documentation of PDDIs by prescribing HCPs (clinical audit).

Standards for clinical audit
----------------------------

1.  100% of consultations with a prescribing HCP since the patient started their current SACT regimen include a documented Med-Rec.

2.  100% of PDDIs between SACT medicines and other medicines had been acknowledged and documented by a prescribing HCP.

Methodology
===========

Study design, inclusion, and exclusion criteria
-----------------------------------------------

This was a single-centre, retrospective case series study. Patients were selected for inclusion if diagnosed with lung cancer and undergoing a SACT regimen as of 31st March 2016 under the care of the Oncology team (led by Professor Mark Bower and Dr Tom Newsom-Davis) at CWH.

Data collection
---------------

For each patient, every instance of documented patient contact at CWH during their SACT regimen was compiled from the patient records. The chosen start point was the last consultation with a prescribing HCP before starting the current SACT regimen in which a full medicines history was taken. For patients on a maintenance SACT regimen, data were recorded from the last consultation in which a full medicines history was elicited before starting the SACT regimen. The endpoint was the cut-off date of 31st March 2016. Data recorded for each consultation include documentation of medicines being taken and changes to the medicine profile as a result of the consultation.

Identifying PDDIs
-----------------

A 'drug chart' overviewing how the medicine profile changed for each patient during their SACT regimen was then created from the data collection spreadsheet ([Appendix 1](#app1){ref-type="app"}). PDDIs were identified using three primary sources: the British National Formulary (BNF); Summary of Product Characteristics (SPC) at <www.medicines.org.uk>; and the London Cancer Alliance (LCA) protocols for each SACT regimen. Only PDDIs involving a SACT medicine---either the anticancer agent, or any prescribed supportive care medicine---were noted, and not between any two non-SACT medicines taken concurrently. Component drugs within a preparation were studied individually.

Assessment of Med-Rec and documentation of PDDIs
------------------------------------------------

The same patient consultation records were analysed for documentation both of Med-Rec being performed and of any DDIs by prescribing HCPs.

Definitions
-----------

'PDDI' (potential drug--drug interaction) is defined as a possible DDI between two medicines (as reported in the BNF, SPC, or LCA protocols) that may have occurred when the patient was taking both concurrently.

'Anticipated DDI' is defined as a possible DDI that was identified but did not occur due to intervention before both medicines were being taken simultaneously. There is therefore no possibility of an adverse event due to this DDI occurring.

A DDI is 'identified' if noted by the author during retrospective analysis of the collected data; 'acknowledged' or 'documented' DDIs are those identified and written down during a consultation by a prescribing HCP.

Results
=======

Twenty-three patients met the criteria for inclusion in this study. SACT regimens being followed, listed by route of administration, are shown in [Table 2](#table2){ref-type="table"}.

Identified PDDIs
----------------

A total of 88 instances of PDDIs involving SACT medicines across 21 patients were identified. This total includes anticipated DDIs (n = 13). [Figure 2](#figure2){ref-type="fig"} presents the SACT medicines with at least one identified PDDI.

In order to present these data qualitatively, PDDIs were grouped based on effect of interaction and mechanism of the interacting medicine. These 30 distinct DDIs are summarised in [Table 3](#table3){ref-type="table"}.

The most common identified DDI was that of dexamethasone + antihypertensives (12.5%), followed by: platinum-based compounds + nephrotoxic drugs (8.0%); crizotinib + UGT substrates, dexamethasone + antidiabetics; pemetrexed + nephrotoxic drugs (each 6.8%). The remaining PDDIs had five or fewer instances. In terms of severity, there were six 'potentially serious' DDIs, equating to 8.0% of the total number.

Medicines reconciliation and documentation of PDDIs
---------------------------------------------------

Standard 1: 100% of consultations with a prescribing HCP since the patient started their current SACT regimen include a documented Med-Rec.

Outcome 1 (standard not met): 3.0% of consultations with a prescribing HCP since the patient started their current SACT regimen include a documented Med-Rec.

A total of 480 instances of documented patient contact were recorded across all 23 patients. Forty-eight of these were excluded from further analysis: eight were phone calls, three were radiology scan appointments, and 37 were consultations with non-prescribing HCPs.

Of the remaining 432 instances, 13 (3.0%, across 7 patients) included a documented Med-Rec. Additionally, 95.7% of patients had at least one full medicines history elicited by a prescribing HCP. This translates to a full medicines history being taken in 11.8% of consultations.

Standard 2: 100% of identified PDDIs between SACT medicines and other medicines had been acknowledged and documented by a prescribing HCP.

Outcome 2 (standard not met): 15.9% of identified PDDIs between SACT medicines and other medicines had been acknowledged and documented by a prescribing HCP.

Of the 88 instances of PDDIs, 14 (15.9%, across 8 patients) were acknowledged and documented. These are summarised in [Table 4](#table4){ref-type="table"}.

Comparison of severity and probability of documentation was performed using Fisher's exact test. Instances of PDDI with an unknown severity (*n* = 30 across both documented and non-documented DDIs) were omitted. Using a standard alpha-level of 0.05, the null hypothesis can be rejected (d.f.=1, two-tailed *p* = 0.019), indicating that potentially serious DDIs were significantly more likely to be documented.

Documented PDDIs were also analysed in relation to Med-Rec processes. None of the 14 PDDIs were acknowledged by a prescribing HCP in the same consultation as a documented Med-Rec. Two (14.3%) were elicited after a full medicines history was taken in the same consultation.

Thirteen of the 14 documented PDDIs can be considered anticipated DDIs, where intervention took place before the interaction could occur. The remaining one instance, gefitinib + warfarin, was acknowledged and documented after both medicines were taken concurrently.

Discussion
==========

Identified PDDIs
----------------

The wide-ranging nature of this study means there are several different aspects suitable for analysis. Firstly, the variety of SACT regimens---10 in total---confirm the multitude of treatment options for late-stage lung cancer patients and compare reasonably well with national statistics \[[@ref16]\].

Regarding the interactions, nearly all patients (91.3%) had at least one identified PDDI, highlighting the importance of characterising them well. Of particular significance were the PDDIs involving supportive care medicines, which accounted for 55% of the total. Most previous studies looking at DDIs involving chemotherapy only consider the anticancer agent \[[@ref50], [@ref51], [@ref54]\], although van Leeuwen did report supportive care medicines to be involved in 86% of all identified PDDIs for the cohort studied \[[@ref55]\], further supporting their clinical relevance in DDIs.

The major SACT medicine of note here was dexamethasone, which comprised 39% of the total number. Moreover, two further PDDIs were identified involving dexamethasone prescribed separately from the SACT regimen. DDIs with corticosteroids have been reported in the literature---van Leeuwen's retrospective study found that dexamethasone was the major supportive care medicine involved \[[@ref55]\], and Lam considered it a 'cancer-related drug' with a variety of mechanisms of interaction \[[@ref49]\]. Additionally, a quarter of PDDIs involving dexamethasone were classified as potentially serious. This raises the question of its safety, particularly as it was a prescribed component of all intravenous combination SACT regimens for these patients ([Appendix 2](#app2){ref-type="app"}). However, regimens are carefully designed in terms of dose, timing, and frequency to minimise harm, with low-dose dexamethasone being taken for only three days for every cycle in these LCA-approved regimens. Nevertheless, caution should be exercised considering the wide range of drugs with which it potentially interacts, especially antihypertensives, which was the single-most common PDDI. Indeed, the high frequency reflects the high prevalence of hypertension in the population, particularly the elderly \[[@ref63]\] and therefore suggests it is an important comorbidity to consider.

The next most commonly involved SACT medicine were the platinum-based compounds. This meant that cisplatin and carboplatin were the anticancer agents with the most PDDIs, a finding corroborated by Mouzon in a retrospective study \[[@ref50]\] and a review by Scripture \[[@ref29]\]. All PDDIs for these were linked with nephrotoxicity, which was also the potential outcome in the interactions involving pemetrexed, another nephrotoxic anticancer agent. Indeed, combining the PDDIs for all three makes kidney damage the most common potential outcome (20.4%). This is particularly dangerous because patients tend to be older and are more likely to have existing renal impairment \[[@ref64]\], putting them at greater risk.

Other notable interactions are the remaining potentially serious PDDIs. Although only six of the 30 were classified in this way, each with low frequencies and thus constituting only 8.0% of the total PDDIs, possible outcomes such as increased risk of bleeding and adrenal suppression mean they should be actively avoided. It is also important to note that 10 PDDIs (totalling 27 instances) did not have a classified severity because they were identified from sources other than the BNF, and so any number could also be potentially serious DDIs, limiting the validity of the results.

Medicines reconciliation and documentation of PDDIs
---------------------------------------------------

The extent of identified interactions, with each patient on average having four PDDIs involving SACT medicines, highlights the necessity of safe prescribing and maintaining patient safety. Clinical audit was an effective method to measure this, identifying results as below expected. For the first standard, a remarkably low value of 3.0% of consultations including a documented Med-Rec implies there is almost a complete lack of the process occurring. Indeed, this was the case: the 13 documented Med-Recs were only performed when a patient was discharged from CWH, and never in clinic. UK and US guidelines focus primarily on Med-Rec for inpatients, with guidance stating it should be performed for any 'transfer of care', either on admission to hospital, during transfer between wards or on discharge \[[@ref27]\]. There is no formally established procedure for patients in ambulatory care at CWH, including this cohort of lung cancer patients attending regular Oncology clinics.

This implies there is scope for implementation of Med-Rec processes for outpatients. IHI suggest collecting a full medicines history and then reviewing if there have been any changes during the consultation, after which a list can be kept 'on file' and verified for each subsequent appointment \[[@ref65]\]. Several intervention studies have assessed the advantages of reminders for patients to bring in their regular medicines to clinic followed by correction of the medicines list by patients themselves \[[@ref66]--[@ref68]\], all with encouraging results. A further justification to perform Med-Rec for these patients is that attending clinic could be seen as a 'temporary' transfer of care, during which the processes of Med-Rec should be carried out.

These shortcomings are also reflected in the second standard regarding PDDI documentation. This again fell well below 100%, suggesting prescribing HCPs do not regularly review the safety of medicines being taken by the patient. Moreover, some were acknowledged simultaneously, meaning the 14 documented PDDIs were across eight consultations only. This below-standard practice could be due to the assumption made by HCPs that reviewing medicines comes under the remit of Pharmacy; involving pharmacists in a multidisciplinary team to ensure accurate medicines lists could improve the documentation of PDDIs and thus prevention of interactions, as seen in Lopez-Martin's single-centre study in Oncology outpatients \[[@ref61]\].

While increasing documentation of PDDIs is clearly key, there were some interesting patterns in the acknowledgement of certain categories. The results revealed the potentially serious interactions were significantly more likely to be documented than non-serious PDDIs. There are also three classes of interacting medicine that constitute the majority (71.4%) of the documented interactions: anticoagulants, PPIs, and antiretrovirals. This suggests that there may be awareness about certain types of DDI involving specific drugs, without the need for research.

Finally, combining the aspects of the study, it appears that performing Med-Rec does not determine whether PDDIs are documented, which was reasonably assessed by the occurrence of both processes in the same consultation. However, this does not take into account the fact that Med-Rec may not always be carried out in a consultation, even though face-to-face Med-Rec is recommended in local guidelines \[[@ref41]\]; it could feasibly be done by comparing to the current medicines list without patient input. This means that there is possible underreporting of Med-Rec, potentially skewing results. Despite this, even just 'verification' correlates poorly (14.3%) with documentation of PDDIs, suggesting that the majority of acknowledged PDDIs were independent of the taking of a full medicines history in that consultation. Thus, it is beneficial to look at some of the many techniques already established to improve identification of potential interactions, such as the pharmacist-led PINCER \[[@ref69]\], the screening tools for elderly patients STOPP/START \[[@ref70]\], and My Medicines Passport, a patient-oriented booklet for recording medicines launched in CWH \[[@ref71]\].

Conclusion
==========

In summary, this study provides a broad review of the common and potentially serious DDIs between SACT medicines and other medicines taken in a cohort of lung cancer patients. It also confirms the lack of established procedure for Med-Rec in these patients and highlights the scope for improvement in identifying more potential interactions, particularly as cancer patients are at risk of polypharmacy. However, the multidisciplinary care required in oncology, including general practice, must be taken into account; thus, implementing these processes in a hospital setting would not eliminate all risk of drug-related harm, but rather, contribute to the bigger picture of ensuring safe medicine prescribing across the whole of the patient journey.

Ethical considerations
======================
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  ----------------------------------------------------------------------------------------------------------------------------
  SACT regimen                     Route of regimen       Supportive care medicines used   Route of supportive care medicine
  -------------------------------- ---------------------- -------------------------------- -----------------------------------
  Pemetrexed\                      Intravenous            Folic acid                       Oral
  (maintenance)                                                                            

  Ondansetron                      Intravenous and oral                                    

  Vitamin B12 (hydroxocobalamin)   Intramuscular                                           

  Pemetrexed + cisplatin           Intravenous            Aprepitant                       Oral

  Dexamethasone                                                                            

  Domperidone                                                                              

  Folic acid                                                                               

  Magnesium sulphate               Intravenous                                             

  Ondansetron                      Intravenous and oral                                    

  Vitamin B12 (hydroxocobalamin)   Intramuscular                                           

  Gemcitabine + carboplatin        Intravenous            Domperidone                      Oral

  Dexamethasone                    Intravenous and oral                                    

  Ondansetron                                                                              

  Nivolumab                        Intravenous            None                             N/A

  Etoposide +\                     Intravenous            Dexamethasone                    Intravenous
  carboplatin                                                                              

  Ondansetron                                                                              

  Pemetrexed + carboplatin         Intravenous            Aprepitant                       Oral

  Dexamethasone                                                                            

  Domperidone                                                                              

  Folic acid                                                                               

  Magnesium sulphate               Intravenous                                             

  Ondansetron                      Intravenous and oral                                    

  Vitamin B12 (hydroxocobalamin)   Intramuscular                                           

  Gefitinib                        Oral                   None                             N/A

  Erlotinib                        Oral                   None                             N/A

  Crizotinib                       Oral                   None                             N/A

  Carboplatin + vinorelbine        Intravenous and oral   Aprepitant                       Oral

  Dexamethasone                    Intravenous and oral                                    

  Ondansetron                                                                              

  Magnesium sulphate               Intravenous                                             

  Potassium chloride                                                                       

  Docetaxel +\                     Intravenous and oral   Domperidone                      Oral
  nintedanib                                                                               

  Dexamethasone                    Intravenous and oral                                    

  Ondansetron                                                                              
  ----------------------------------------------------------------------------------------------------------------------------

![Most common SACT regimens for lung cancer between January and December 2014. Key: GEMCARBO=gemcitabine + carboplatin. Taken from \[[@ref16]\].](can-11-764fig1){#figure1}

![Frequency of PDDIs (total n = 88) for each of the 13 SACT medicines that had at least one identified PDDI.](can-11-764fig2){#figure2}

###### Summary of anticancer agents used in lung cancer with indications, class and mechanism of action. Taken and adapted with kind permission from \[[@ref6]\], contributions from \[[@ref1], [@ref2], [@ref4], [@ref7]--[@ref15]\].

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Anticancer agent                             Indication(s) in lung cancer                                                               Class of anticancer agent                                                                                                                                              Main mechanism
  -------------------------------------------- ------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------
  Cyclophosphamide                             Extensive SCLC                                                                             Nitrogen mustard                                                                                                                                                       Intrastrand cross linking of DNA

  Carboplatin, cisplatin                       Stage I--II NSCLC (adjuvant)                                                               Platinum-based compound                                                                                                                                                

  Stage IIIb--IV NSCLC (palliative)                                                                                                                                                                                                                                                                              

  All-stage SCLC (palliative)                                                                                                                                                                                                                                                                                    

  Pemetrexed                                   Stage IIIb--IV non-squamous NSCLC\                                                         Folate antagonist                                                                                                                                                      Blocking the synthesis of DNA and/or RNA
                                               (first line)                                                                                                                                                                                                                                                      

  Gemcitabine                                  Stage IIIb--IV squamous NSCLC (first-line)                                                 Pyrimidine pathway antimetabolite                                                                                                                                      

  Doxorubicin                                  Extensive SCLC                                                                             Anthracycline                                                                                                                                                          Multiple effects on DNA/RNA synthesis and topoisomerase action

  Docetaxel, paclitaxel                        Stage IIIb--IV NSCLC (first line)                                                          Taxane                                                                                                                                                                 Microtubule assembly; prevents spindle formation

  Vincristine                                  Extensive SCLC                                                                             Vinca alkaloid                                                                                                                                                         

  Vinorelbine                                  Stage IIIb--IV squamous NSCLC (first line)                                                                                                                                                                                                                        

  Topotecan                                    Relapsed SCLC                                                                              Campothecin                                                                                                                                                            Inhibition of topoisomerase

  Etoposide                                    All-stage SCLC (palliative)                                                                Other plant derivative                                                                                                                                                 

  Afatinib, erlotinib, gefitinib               Stage IV--NSCLC + EGFR mutation\                                                           Epidermal growth factor receptor\                                                                                                                                      Inhibition of kinases involved in growth factor receptor transduction
                                               (first line)                                                                               (EGFR)-tyrosine kinase inhibitor (TKI)                                                                                                                                 

  Stage IV NSCLC (second line if refractory)                                                                                                                                                                                                                                                                     

  Crizotinib                                   Stage IIIb--IV NSCLC + ALK translocation (second line)                                     Anaplastic lymphoma kinase (ALK) inhibitor                                                                                                                             

  Nintedanib                                   Stage IIIb--IV non-squamous NSCLC (second line, if progressive disease after first line)   Vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-3) and platelet-derived growth factor receptor (PDGFRα,β) inhibitor   

  Nivolumab                                    Stage IV squamous and non-squamous NSCLC                                                   Anti-programmed cell death-1\                                                                                                                                          Recruitment of T cells
                                                                                                                                          (PD-1) monoclonal antibody                                                                                                                                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### SACT regimens of all patients (n = 23).

  SACT regimen                          Frequency (%)
  ------------------------------------- ---------------
  **Intravenous**                       **14 (60.9)**
  -- Pemetrexed (maintenance)           -- 7 (30.4)
  -- Post-pemetrexed + cisplatin        -- 6 (26.1)
  -- Post-gemcitabine + carboplatin     -- 1 (4.3)
  -- Nivolumab                          -- 3 (13.0)
  -- Gemcitabine + carboplatin          -- 2 (8.7)
  -- Etoposide + carboplatin            -- 1 (4.3)
  -- Pemetrexed + carboplatin           -- 1 (4.3)
  **Oral**                              **7 (30.4)**
  -- Gefitinib                          -- 4 (17.4)
  -- Erlotinib                          -- 2 (8.7)
  -- Crizotinib                         -- 1 (4.3)
  **Combined (intravenous and oral)**   **2 (8.7)**
  -- Carboplatin + vinorelbine          -- 1 (4.3)
  -- Docetaxel + nintedanib             -- 1 (4.3)

###### Summary of the identified PDDIs (*n*=30). Key: UGT=UDP-glucuronosyltransferase; ACEIs=angiotensin-converting enzyme (ACE) inhibitors; CCBs=calcium channel blockers; ARBs=angiotensin-II receptor blockers; PPIs=proton pump inhibitors.

  SACT medicine                                        Interacting (class of) drug                                                                                    Possible outcome (effect of interaction)                                               Severity of interaction   n
  ---------------------------------------------------- -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- ------------------------- ----
  Aprepitant                                           Ritonavir                                                                                                      Aprepitant toxicity (increased exposure)                                               Non-serious               1
  Warfarin                                             Reduced anticoagulation (reduced exposure to warfarin)                                                         Non-serious                                                                            1                         
  Crizotinib                                           UGT substrates (amoxicillin, colecalciferol, diazepam, levomepromazine, metoclo-pramide, mirtazapine)          Various (increased exposure to UGT substrates)                                         Unknown                   6
  Dexamethasone                                        Poor crizotinib efficacy (reduced exposure)                                                                    Unknown                                                                                1                         
  Dexamethasone                                        Antihypertensives (ACEIs, CCBs, ARBs, beta-blockers, nitrates)                                                 Raised blood pressure (antagonised effect of antihypertensives)                        Non-serious               11
  Antidiabetics (metformin, gliclazide, linagliptin)   Raised blood glucose (antagonised effect of antidiabetics)                                                     Non-serious                                                                            6                         
  Diuretics (furosemide, bendroflumethiazide)          Hypokalaemia and associated signs and symptoms                                                                 Non-serious                                                                            5                         
  Aspirin                                              Gastrointestinal bleeding and ulceration (reduced exposure to salicylate)                                      Non-serious                                                                            5                         
  Calcium carbonate                                    Hypocalcaemia and associated signs and symptoms (reduced exposure to calcium salts)                            Non-serious                                                                            4                         
  Coumarins                                            Enhanced (high-dose corticosteroids) or reduced anticoagulation (increased or reduced exposure to coumarins)   Potentially serious                                                                    1                         
  Phenindione                                          Enhanced or reduced anticoagulation (increased or reduced exposure to phenindione)                             Non-serious                                                                            1                         
  Ritonavir                                            Adrenal suppression (increased exposure to corticosteroids)                                                    Potentially serious                                                                    1                         
  Docetaxel                                            CYP3A inhibitors (paracetamol, PPIs)                                                                           Docetaxel toxicity (increased exposure)                                                Unknown                   2
  Clarithromycin                                       Myelosuppression; docetaxel toxicity (increased exposure)                                                      Potentially serious                                                                    1                         
  Domperidone                                          Opioid analgesics (codeine, morphine)                                                                          Gastroparesis (antagonised gastrointestinal effects of domperidone)                    Non-serious               5
  Clarithromycin                                       Domperidone toxicity (increased exposure to domperidone); ventricular arrhythmias                              Potentially serious                                                                    2                         
  Tiotropium                                           Gastroparesis (antagonised gastrointestinal effects of domperidone)                                            Non-serious                                                                            1                         
  Erlotinib                                            PPIs/H2 antagonists/antacids (lansoprazole, ranitidine, sodium bicarbonate)                                    Poor efficacy (reduced exposure to erlotinib)                                          Unknown                   3
  Statins                                              Myopathy                                                                                                       Unknown                                                                                1                         
  Folic acid                                           Sodium bicarbonate                                                                                             Folate deficiency and associated signs and symptoms (reduced exposure to folic acid)   Non-serious               2
  Gefitinib                                                                                                                                                                                                                                                                            
  CYP3A4 inhibitors (diclofenac, clindamycin)          Gefitinib toxicity (increased exposure)                                                                        Unknown                                                                                2                         
  PPIs (lansoprazole, omeprazole)                      Poor gefitinib efficacy (reduced exposure)                                                                     Unknown                                                                                2                         
  CYP3A4 inducers (nevirapine, flucloxacillin)         Poor gefitinib efficacy (reduced exposure)                                                                     Unknown                                                                                2                         
  Warfarin                                             Enhanced anticoagulation (increased exposure to warfarin)                                                      Potentially serious                                                                    1                         
  Nivolumab                                            Dexamethasone                                                                                                  Systemic immunosuppression                                                             Unknown                   1
  Ondansetron                                          Sertraline                                                                                                     Enhanced serotonergic effects                                                          Non-serious               1
  Pemetrexed                                           Nephrotoxic drugs (ibuprofen, ACEIs, sulphamethoxazole)                                                        Nephrotoxicity; pemetrexed toxicity (increased exposure)                               Non-serious               6
  Platinum-based compounds (cisplatin, carboplatin)    Nephrotoxic drugs (aspirin, ibuprofen, ACEIs, sulphamethoxazole)                                               Nephrotoxicity                                                                         Unknown                   7
  Diuretics (bendroflumethiazide, furosemide)          Nephrotoxicity; ototoxicity                                                                                    Non-serious                                                                            5                         
  Potassium chloride                                   Irbesartan                                                                                                     Hyperkalaemia and associated signs and symptoms                                        Potentially serious       1

###### Summary of acknowledged and documented instances of PDDIs (*n* = 14).

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient \#      SACT medicine   Interacting medicine                                                                   Effect of interaction                          Severity of interaction
  --------------- --------------- -------------------------------------------------------------------------------------- ---------------------------------------------- -------------------------
  1               Aprepitant      Ritonavir                                                                              Increased exposure to aprepitant               Non-serious

  Dexamethasone   Ritonavir       Increased exposure to corticosteroids, causing increased risk of adrenal suppression   Potentially serious                            

  2               Nivolumab       Dexamethasone                                                                          Increased risk of systemic immunosuppression   Unknown

  3               Aprepitant      Warfarin                                                                               Reduced anticoagulant effect of warfarin       Non-serious

  Dexamethasone   Coumarins       Enhanced (high-dose corticosteroids) or\                                               Potentially serious                            
                                  reduced anticoagulant effect of coumarins                                                                                             

  Dexamethasone   Phenindione     Enhanced or reduced anticoagulant effect of phenindione                                Non-serious                                    

  4               Gefitinib       Warfarin                                                                               Enhanced anticoagulant effect of warfarin      Potentially serious

  5               Gefitinib       Lansoprazole                                                                           Reduced exposure to gefitinib                  Unknown

  6               Gefitinib       Flucloxacillin                                                                         Reduced exposure to gefitinib                  Unknown

  7               Erlotinib       Lansoprazole                                                                           Reduced exposure to erlotinib                  Unknown

  Erlotinib       Statin          Increased risk of myopathy                                                             Unknown                                        

  8               Gefitinib       Nevirapine                                                                             Reduced exposure to gefitinib                  Unknown

  Gefitinib       Omeprazole      Reduced exposure to gefitinib                                                          Unknown                                        

  Gefitinib       Diclofenac      Increased exposure to gefitinib                                                        Unknown                                        
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
